Hengyu Medical Secures Tens of Millions in Funding to Accelerate R&D and Commercialization of Endovascular Intraluminal Diagnostic and Therapeutic Products

VCBeat learned that recently, Horimed Technology Co., Ltd. (hereinafter referred to as "Horimed") announced the completion of a multi-million yuan financing round. This round was led by existing shareholder Tasly Capital Holding (Beijing) Co., Ltd., with participation from the biopharmaceutical fund jointly established by Haihe Fund and HAITAI Capital. HAOYUE CAPITAL continued to serve as the exclusive financial advisor.This round of financing will support R&D, production, and registration, with a focus on accelerating the commercial promotion of already listed products.

Founder of Horimed, Mr. Liu ZhiyongExpressed gratitude to both new and existing shareholders for their unwavering support, stating that China's vascular interventional precision diagnosis and treatment industry is still in its infancy, and Horimed still has a long way to go. With the support of capital, the company believes that it will become a leading enterprise in intelligent intravascular interventional diagnosis and treatment through its solid, innovative technology and products.

Dr. Shi-Yong Zhao, Founder of HorimedHorimed stated that while focusing on technology and products in the future, it will also concentrate on assisting clinical teams with systematic training for precise vascular intervention diagnosis and treatment. This will enable an increasing number of doctors to understand, master, and promote precise vascular intervention diagnosis and treatment. Horimed actively responds to national policies by participating in the IVUS bulk procurement and successfully being selected, allowing more patients to access high-quality and affordable intravascular ultrasound diagnostics. At the same time,Horimed's IVUS and OCT integrated machine is also facilitating the implementation of volume-based procurement equipment, allowing more cardiovascular intervention centers to simultaneously utilize both advanced intravascular precision technologies, OCT and IVUS., improve China's clinical technical level in this field, and ultimately benefit more patients.

Mr. Wang Chen, Managing Partner of Tasly Capital Holding (Beijing) Co., Ltd.In recent years, the development of intravascular imaging technology, particularly the progress of AI technology platforms and the future trend of integration with intravascular imaging products, has demonstrated increasingly significant value in the diagnosis, evaluation, treatment, and complication detection of various types of coronary heart disease in clinical practice. It is an essential tool for precise PCI, especially playing a substantial role in optimizing the treatment of complex lesions, such as bifurcation lesions, calcified lesions, and restenosis lesions. Additionally, with the advancement of the "intervention without implant" concept, the prospects for intravascular laser ablation products are promising, offering better technical options for patients with severe blockages, calcifications, and stent restenosis. Horimed Technology Co., Ltd., which possesses these technology platforms, is a top-tier company in China guided by clinical needs and driven by research and development. Tasly Capital Holding (Beijing) Co., Ltd. will continue to support the development of Horimed, helping to provide better treatment technologies for cardiovascular patients.

Ms. Li Chao, General Manager of HAITAI CAPITALWith the rapid development of interventional diagnosis and treatment technology for coronary heart disease, intracoronary imaging has gradually become a powerful tool to assist doctors in completing interventional diagnosis and treatment. It plays an important role in the research on the mechanisms of coronary heart disease, as well as in guiding and optimizing each step of interventional diagnosis and treatment. Horimed is the domestic enterprise with the most comprehensive product line in the field of intravascular imaging and represents an outstanding medical device company in Tianjin. HAITAI Capital will continue to support the development of Horimed Technology Co., Ltd. in Tianjin, helping more patients with coronary heart disease.